NBC Securities’s C4 Therapeutics CCCC Stock Holding History

NBC Securities’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10.5K	Hold	4,000	–	–	﹤0.01%	1923
2025 Q4	$7.64K	Buy	+4,000	New	+$9.48K	﹤0.01%	2095

Other funds holding CCCC

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

NBC Securities's CCCC Position: Q1 2026 in Review

NBC Securities held its C4 Therapeutics (CCCC) position steady in Q1 2026 at 4,000 shares worth $10.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1923.

NBC Securities first reported a position in CCCC in Q4 2025 and has held it in 2 quarters since. 123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

NBC Securities held 4,000 shares of C4 Therapeutics worth $10.5K as of Q1 2026.
NBC Securities left its C4 Therapeutics share count unchanged in Q1 2026.
C4 Therapeutics made up ﹤0.01% of NBC Securities's portfolio in Q1 2026, its #1923 holding.
NBC Securities first reported a position in C4 Therapeutics in Q4 2025 and has held it in 2 quarters since.
123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on NBC Securities's 13F filing for Q1 2026, filed 14 Apr 2026.